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Abstract 
Introduction: The population of adults with congenital heart disease (ACHD) is rapidly expanding and 
one of the major complications is heart failure. Timely diagnosis and treatment are crucial, but strong 
evidence for effectiveness of heart failure treatment in ACHD is currently lacking. Components of the 
medical history, physical examination and further diagnostic tests including ECG, echocardiography, 
cardiac magnetic resonance imaging, exercise testing, and biomarkers can identify patients at risk for 
early mortality or heart failure. 
Areas covered: Although the number of studies guiding evidence-based treatment are expanding, many 
clinical questions have not been completely answered yet. Therefore, in this review we provide an 
overview of current available insights in epidemiology, diagnosis, risk stratification and treatment 
options in ACHD patients, including non-medical therapies and advanced care planning.  
Expert Opinion: We strongly advocate expanding current use of biomarkers in the diagnostic process 
and timely initiation of discussing advanced treatment options and advanced care planning with patients 
and their loved ones. More research in multi-center collaborations is needed to study all aspects of care 
of adult congenital heart disease patients.  
 
Keywords: Risk stratification; Prognosis; Diagnosis; Biomarkers; Heart failure; Treatment; Congenital 
Heart Defects; Predictors. 
 
Article highlights  
 Nowadays, most CHD patients will survive into adulthood due to the astonishing improvement in care. 
 Heart failure is an important and increasingly prevalent clinical issue in ACHD patients.  
 Biomarkers are the cornerstone of heart failure diagnosis.  
 There are currently no large clinical trials guiding clinical treatment of heart failure, so multicenter 
collaboration is essential.  
 Advanced care planning is essential and should be discussed early with our patients and their loved 
ones.  
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1. Introduction and epidemiology   
Congenital heart disease (CHD) is the most common congenital abnormality diagnosed in newborns and 
lifelong specialist follow-up and often repeated surgical or interventional procedures are required [1]. 
There has been a substantial increase in the reported birth prevalence of CHD over time, with a reported 
incidence of 9.1 per 1.000 live births after 1995 [2]. There are significant geographical differences, with 
Europe having the second highest incidence (8.2 per 1.000 live births). Worldwide, 1.5 million children 
with CHD are born each year. Among them, 55% will have a simple heart defect, the remaining 45% 
having a defect of moderate or great complexity [3]. 
Due to the major advances in cardiothoracic surgery, pediatric cardiology and intensive care medicine in 
the past decades, most patients born with a CHD defect will survive into adulthood. In 2014, an 
estimated 1 million adults with CHD were living in the European Union [4], an estimated prevalence of 3 
per 1000 [5].  Importantly, there has been an increase in the prevalence of CHD in patients beyond 60 
years of age from 0.5% in 2000 to 5.1% in 2012 [4], to an estimated 11% when extrapolated to 
2030  (figure 1). Since there is a high morbidity and mortality in this specific patient group, this will have 
a major impact upon organization of care and health care costs [6].   
  
  
Figure 1. Changing prevalence of Congenital Heart Disease (CHD) in the European Union by age group. 
The rough estimates of the total population of children, adult patients 18-60 and adult patients >60 
years with CHD are based on published birth rates (in 2008) and consider only patients born after 1970, 
ignoring adult mortality. Assumptions are based on currently reported survival into adulthood8, reported 
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rates of patients >60 years and records of the German Competence Network for Congenital Heart 
Disease. ACHD: Adult Congenital Heart Disease. Reproduced with permission. [4] 
Despite this spectacular increase in life expectancy complications occur often including heart failure, 
arrhythmias and stroke, necessitating lifelong specialized care and follow-up [7].   
There are many potential factors contributing to the development of heart failure in CHD patients. 
Valvar abnormalities, shunt lesions, inflow or outflow tract obstruction, arrhythmia, persistent 
anatomical defects, abnormal loading conditions or cyanosis all have the potential to compromise 
cardiac function. Subsequent neurohumoral activation, myocardial fibrosis and adverse remodeling will 
lead to a progressive deterioration of cardiac function and the clinical syndrome of heart failure [8, 9].   
The prevalence of heart failure in patients with adult congenital heart disease (ACHD) varies according 
to the underlying structural anomaly. In adults with a repaired Tetralogy of Fallot (ToF), there is a 
marked increase in prevalence of heart failure, ranging from 31.7% in patients aged 20-29 years old to 
52.9% in patients over 50 [10]. There is also a clear increase with age of the prevalence of heart failure 
in patients with a transposition of the great arteries after atrial switch procedure. The probability of 
developing heart failure is about 25% in patients aged 20, 40% in patients aged 30 to almost 60% in 
patients aged 40 [11]. However, other studies report a lower prevalence of 23% during a median follow-
up period of up to 35 years [12, 13].  Nevertheless, this number might increase even further in the near 
future, since a progressive deterioration of the systemic right ventricle in these patients is a well-known 
and unavoidable phenomenon [14]. In patients with a congenitally corrected transposition of the great 
arteries (ccTGA), the reported prevalence of heart failure by age 45 is 25% in patients without associated 
lesions and 76% in patients with associated lesions [15].  In patients with a single ventricle morphology 
after Fontan palliation, a prevalence of up to 40% is described during a mean post-operative follow-up 
period of 16 years, with patients having right ventricular morphology being especially at risk [16, 17]. 
Fortunately, in patients with less complex defects and systemic left ventricle morphology, a much lower 
prevalence is described, ranging from 2% in patients aged 30 with a repaired coarctation to 11% in 
patients with left to right shunt lesions [11].       
Heart failure comprises a substantial burden of morbidity and utilization of resources. The reported 
incidence of first hospital admission for heart failure in ACHD patients was 1.2 per 1000 patient years in 
the Dutch national CONCOR registry [17]. In another study, heart failure accounted for 20% of all ACHD 
related hospital admissions [18]. Patients admitted for heart failure tend to have a longer hospital stay 
(12.2 days), are frequently admitted at the intensive care unit (25%) and more frequently readmitted 
(18%) [19]. Burchill et al described an increase in ACHD hospitalization rate of 91% between 1998 and 
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2001 with a 258% increase in ACHD heart failure hospitalization rate, which is twice as much as for non-
ACHD heart failure admissions[20].  
Finally, heart failure has become the leading cause of death in patients with ACHD, with a reported 
relative contribution ranging between 17% - 42%[17, 21, 22, 23, 24, 25, 26]. In figure 2, we summarized 
a number of trials investigating the mechanism of death in patients with ACHD. In 24.694 patients with 
ACHD, 1573 patients died. In 28.6%, heart failure was the mechanism of death [17, 21, 22, 24, 26].   
  
 
 Figure 2. Mechanism of death in 1573 adult patients with congenital heart disease. See text for 
references.  
   
The abovementioned data emphasize the emerging importance of the clinical syndrome of heart failure 
amongst patients with ACHD. However, due to the significant heterogeneity in underlying cardiac 
anatomy, but also surgical and interventional history, clinical presentation varies widely, and the full 
scope of heart failure is likely to be underestimated. This is confirmed in multiple studies that have 
demonstrated VO2 max in ACHD patients to be diminished, regardless of NYHA class and underlying 
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cardiac anomaly[27, 28]. Subsequently we may greatly underestimate the true prevalence of (sub-
clinical) heart failure and substantial efforts should be made to identify those patients at risk and those 
in the early stages of heart failure.   
 
2. Diagnosis of heart failure in ACHD 
 
Defining heart failure in ACHD can be challenging and might be influenced by patient and physician 
factors. The definition in the 2016 ESC Guidelines is as follows: “ a clinical syndrome characterized by 
typical symptoms (…) that may be accompanied by signs (…) caused by a structural and/or functional 
cardiac abnormality, resulting in a reduced cardiac output and/or elevated intra-cardiac pressures at 
rest or during stress [9].” It can be easily appreciated that ACHD patients all have a structural 
abnormality which is often accompanied by elevated cardiac pressures [29]. Also, many patients have 
been adapting to their condition since birth. This lifelong adaptation may lead to a patient-specific 
adjustment and may mask their awareness of heart failure symptoms. As a result, signs and symptoms 
indicative of heart failure may not be reported to their physician. The guidelines differentiate between 
heart failure with reduced ejection fraction (HFREF) and heart failure with preserved ejection fraction 
(HFPEF), also known as diastolic dysfunction. The presence of HFPEF and its role in ACHD patients is not 
well investigated, although in specific cohorts such as Fontan patients some research is becoming 
available [30]. 
Diagnosis of heart failure in ACHD should consist of a comprehensive evaluation of signs and symptoms, 
diagnostic testing and medical history, as advised by the 2016 ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure. In ACHD patients, the guidelines do not offer any specific 
recommendations, but, as always, a patient-tailored approach is essential. Consultation with both ACHD 
and heart failure specialists is often helpful and constructive to evaluate the complex situation of these 
patients and to optimize diagnosis and treatment. 
Symptoms and signs are often nonspecific and can be different from heart failure symptoms in the 
general population due to the relatively younger age and more complex (cardiac) history of the ACHD 
population, including a higher percentage of right heart failure [31]. Symptoms of heart failure include, 
but are not limited to, shortness of breath, fatigue, loss of energy, orthopnea, palpitations, postural 
nocturnal dyspnea, diminished exercise capacity, loss of appetite, weight gain, swollen ankles or 
abdomen and chest discomfort. A thorough history should be taken to elucidate the nature of the 
symptoms, time frame, provoking factors, such as anemia, arrhythmias or substance abuse, and 
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alternative explanations. The aim of the physical examination should be focused on signs of congestion 
and should be repeated at regular intervals during follow-up and treatment.  
Congenital conditions with a predominantly right-sided phenotype and heart failure often exhibit signs 
of systemic venous congestion, such as peripheral edema (ankles, lower legs and abdomen), raised 
jugular venous pressure, hepatic and splenic enlargement and pleural effusion. Conditions associated 
with right- sided congestion include left-to-right shunts (e.g. atrial septal defects), Ebstein’s anomaly 
with severe tricuspid valve regurgitation and Tetralogy of Fallot (ToF) with abnormalities of the 
pulmonary valve, arteries and the right ventricular outflow tract. Importantly, patients with pre-
dominantly right-sided abnormalities such as ToF may also develop left ventricular dysfunction, which 
may in turn cause symptoms [32].  Signs of left-sided causes of heart failure include crackles on lung 
auscultation, third heart sound and a displaced apex beat. It is important to realize that failure of the 
right ventricle and tricuspid valve in systemic right ventricles (e.g. ccTGA or after atrial switch surgery) 
leads to symptoms and signs of pulmonary congestion. In patients after Fontan procedure with a 
univentricular heart systemic congestion often predominates, related to elevated pressures in the 
Fontan circulation. 
Initial diagnostic tests include electrocardiography, transthoracic echocardiogram and laboratory testing 
(e.g. hemoglobin, kidney and thyroid function and natriuretic peptides). Often, additional testing will be 
required to assess myocardial function, valvar function, exercise tolerance and heart rhythm 
abnormalities [33, 34]. These include, but are not limited to, cardiac magnetic resonance imaging, 
computer tomography scan, transesophageal echocardiography, cardiopulmonary exercise testing, tape 
monitoring and other forms of heart rhythm analysis such as implantable loop recorders (see table 
diagnosis).  
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Indications Limitations 
Electrocardiogram Sinus rhythm; atrial arrhythmias, e.g. atrial fibrillation; conduction delay May not show paroxysmal arrhythmias 
Laboratory testing Kidney, liver and thyroid function; hemoglobin; infection parameters; 
clotting function; specific heart failure biomarkers 
 
Transthoracic echocardiogram Myocardial contractile function; diastolic function; valvar function; intra-
cardiac pressures; pulmonary pressures; dimensions of great vessels; 
function of baffles and conduits; pericardial fluid 
Poor acoustic windows 
Chest radiography Cardiac size; pleural effusion; hilar enlargement  
Magnetic resonance imaging Ventricular dimensions and function; valvar function; shunt fraction 
(Qp:Qs); baffle and conduit function; anatomic relationships 
Artefacts from implants, claustrophobia 
Computer tomography Anatomic relationships; dimensions of vessels and structures Possible use of iodine-based contrast 
agent, irradiation 
Transesophageal 
echocardiography 
Anatomic relationships; valvar function; intra-cardiac shunts Semi-invasive 
Cardiopulmonary exercise 
testing 
Exercise capacity; rhythm disturbances; blood pressure at exercise Inability to exercise  
Tape monitoring Heart rate frequency; atrial and ventricular rhythm abnormalities such as 
ectopic beats; atrial tachycardia and fibrillation and (non-sustained) 
ventricular tachycardia 
May not show paroxysmal arrhythmias 
Blood pressure recording Readings during day and night and during different activities  
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Coronary angiography Course and condition of coronary arteries Invasive, use of iodine-based contrast 
agent, irradiation 
Left heart catheterization Pressures and gradients at different locations, such as mitral valve, left 
ventricle, aortic valve, coarctation 
Invasive 
Right heart catheterization Anatomy of venous structures; pressures at different levels, such as caval 
veins, right atrium, right ventricle, pulmonary artery (trunk and branches) 
and wedge pressure; Pressure gradient across pulmonary valve and 
conduits 
Invasive 
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3. Risk stratification 
In ACHD patients many factors are identified as prognostic including ventricular function, the presence 
of pulmonary hypertension, exercise capacity and biomarkers.  The systolic ventricular function is one of 
the most important prognostic parameters and a moderately to severely impaired systemic ventricular 
function is an independent predictor for sudden cardiac death in the overall ACHD population. This is 
also true for patients with a systemic right ventricle. In addition, higher ventricular end-diastolic volumes 
are independently associated with a higher mortality risk in patients with a Fontan circulation and in 
patients with repaired ToF [35, 36, 37]. A substantial proportion of ACHD patients develop pulmonary 
arterial hypertension and elevated pulmonary pressures are also strongly indicative of poor prognosis.  
Lower peak VO2 measured during cardiopulmonary exercise test is associated with a higher risk of 
hospitalization or death or the development of heart failure, and independently predicts mortality, 
indicating that it is a powerful prognostic tool within the entire ACHD population [27, 38].  
In patients with heart failure, natriuretic peptides are firmly established prognostic tools. 
Neurohormonal activation of the natriuretic, endothelin, sympatho-adrenergic, and renin-aldosterone 
systems also occurs in all types of congenital heart disease [39]. Accumulating evidence shows that N-
terminal pro-B-type natriuretic peptide (NT-proBNP) is related to disease severity and that it is useful for 
risk stratification in patients with clinically stable ACHD, even beyond conventional risk markers [40, 41]. 
Interestingly, normal levels of NT-proBNP (<14 pmol/L) can accurately rule out the risk of death and 
heart failure with a high negative predictive value [42]. A position paper from the working group of 
grown-up congenital heart disease and the heart failure association of the European Society of 
Cardiology has therefore suggested that a two-fold increase of baseline NT-proBNP within 6 months is 
regarded as a significant increase which indicates the need for optimization of heart failure medical 
therapy [43]. In the literature different results have been described for the association between NT-
proBNP levels and outcome in patients with a Fontan circulation. Higher levels of NT-proBNP are 
reported, especially in patients with an older Fontan modification (atriopulmonary connection and 
atrioventricular connection) compared to total cavopulmonary connection, independently from cardiac 
status [44, 45], while others found significant higher levels of NT-proBNP in Fontan patients with 
moderate to severely impaired ventricular function [46]. Furthermore, since there are several modes of 
Fontan failure and NT-proBNP reflects a high volume load and myocardial stress, biomarkers 
discriminating between the modes of Fontan failure are needed and in many patients the NT-proBNP 
levels are relatively low.  
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Biomarkers that reflect other pathophysiological mechanisms which are involved in the heart failure 
syndrome, such as high-sensitive troponin-T (hs-TnT) and growth-differentiation factor 15 (GDF-15) are 
also related to the occurrence of heart failure in ACHD patients. In a prospective cohort of 595 patients 
with moderate and complex ACHD, elevated levels of hs-TnT (>14 ng/L, 8% of patients) and GDF-15 
(>1109 ng/L, 15% of patients) could predict outcomes in ACHD patients with elevated levels of NT-
proBNP, suggesting a potential benefit of a multi-marker approach [42]. Other promising novel cardiac 
markers are red cell distribution width, galectin-3 and ST-2[47]. Some studies have focused on specific 
patient groups such as patients with a systemic right ventricle[47]. In Figures 3 and 4 these findings are 
summarized. Few studies have attempted to develop risk prediction models specifically for patients with 
ACHD [38, 48, 49]. 
 
(Figures 3 and 4) 
 
An integral perspective of the patients’ clinical prospects should always be based on a combination of all 
available information, that is composed of the medical history, physical examination, imaging, exercise 
testing and biomarkers. The frequency at which individual patients should be monitored at the 
outpatient clinic and the type and frequency of additional investigations is based on expert opinion in 
specialist centers. 
Although many women with heart disease may be in a stable clinical condition, pregnancy is associated 
with substantial hemodynamic changes that carry an increased risk of cardiac complications, especially 
heart failure. The risk of developing heart failure during pregnancy is strongly influenced by the type of 
heart defect and presence of residual lesions. The modified World Health Organization (mWHO) 
classification seems to be the most accurate tool in predicting these risks [50]. It stratifies patients based 
on their underlying diagnosis into four groups from very low risk patients (mWHO I), to high risk patients 
in whom a pregnancy is thought to be life threatening and therefore contraindicated (mWHO IV) [51]. 
Pregnancy is contraindicated (mWHO IV) in women with pulmonary hypertension, severe cyanosis, 
significantly reduced left ventricular function, previous peripartum cardiomyopathy with incomplete 
recovery, symptomatic left ventricular outflow tract obstruction, and patients with a severely dilated 
aorta [52]. 
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Figure 3. Biomarker levels in adults with congenital heart disease according to the type of congenital heart disease. Combined data previously 
published by Baggen 2017, Baggen 2018, Eindhoven 2015, Geenen 2019 [42, 53, 54, 55] 
Figure legend: For NT-proBNP and GDF-15 the x-axis is on the 2log scale.  
Abbreviations: AoS= aortic stenosis, CoA= coarctation of the aorta, ToF= Tetralogy of Fallot, TGA-ASO= transposition of the great arteries 
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corrected by the arterials witch operation, RV= right ventricle, Univentricular= functionally univentricular hearts , PAH= pulmonary arterial 
hypertension, NT-proBNP= N-terminal pro B-type natriuretic peptide, Hs=high sensitivity, CRP= C-reactive protein, ST2= suppression of 
tumorigenicity-2, GDF-15= growth differentiation factor-15  
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Figure 4. Heart-failure free survival according to the number of abnormal biomarker levels in adults with congenital heart disease. Combined 
data previously published by Baggen 2017, Baggen 2018, Eindhoven 2015, Geenen 2019  [42, 53, 54, 55]  
Figure legend: Included biomarkers and definitions of abnormal levels: NT-proBNP (>14 pmol/L), hs-troponin T (>14 ng/L), hs-CRP (>3 mg/mL), 
sST2 (♂>  55.85 ng/mL, ♀> 44.50 ng/mL), RDW (>16 %), and GDF-15 (>1109 ng/L) 
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4. Treatment 
4.1 General considerations  
So far, no clinical trials on heart failure medication in ACHD patients have demonstrated survival benefit. 
In the most recent ESC guidelines for the treatment of acute and chronic heart failure, no specific 
recommendations regarding patients with ACHD are given [9]. A recently published position paper on 
behalf of the Working Group of Adult Congenital Heart Disease suggests that in the setting of increased 
neurohumoral and cardiac autonomic activity, the use of diuretics, renin-angiotensin-aldosterone 
system (RAAS) blockers, betablockers and mineralocorticoid receptor antagonists might be considered 
[43].    
Since similarities in the pathophysiological process of heart failure in ACHD patients and various forms of 
acquired ventricular systolic dysfunction have been described, therapies that improve the prognosis in 
acquired systolic dysfunction might also be beneficial in selected ACHD patient  [39, 56]. Most profound 
benefit is expected in patients with a two-ventricle physiology with anatomical left ventricular systolic 
dysfunction [8]. Unfortunately, this is not supported by evidence from randomized clinical trials. 
However, we have to highlight that most studies were small and probably underpowered to show an 
effect. Furthermore, the risk of poor tolerance might be increased in patients with ACHD, particularly in 
those with a systemic right ventricle or in patients with a Fontan circulation/univentricular heart.  At 
present, there is no medical treatment with proven benefit for HFPEF in the general cardiology 
population nor in ACHD patients. 
Before initiation of heart failure medication, all patients should undergo an extensive evaluation, 
including a thorough clinical evaluation, electrocardiography, transthoracic echocardiogram and 
laboratory testing, including biomarkers (table 1). Relevant medical comorbidities should be treated, 
common interventions for cardiovascular risk factor modulation, e.g. weight reduction, smoking 
cessation and iron supplementation should be offered [8, 9, 43]. If significant hemodynamic lesions still 
exist, they should be corrected or repaired according to current guidelines [3, 57]. In figure 5, a 
diagnostic and treatment algorithm is suggested.  
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Figure 5: proposed diagnostic and treatment algorithm in ACHD patients with signs/symptoms of heart 
failure.   
Abbreviations: ACHD= Adult Congenital Heart Disease, CRT-D=cardiac resynchronization therapy-
defibrillator, MCS= mechanical support, HTx= heart transplantation 
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4.2 Medical therapy 
 
Betablockers  
A limited number of studies describe the potential beneficial effects of betablockers for heart failure in 
CHD. In children and adolescents with symptomatic systemic ventricular dysfunction, carvedilol showed 
no significant difference in clinical heart failure outcome, although a beneficial trend in patients with a 
systemic left ventricle was observed [58]. In a small study evaluating patients admitted because of heart 
failure with dilated cardiomyopathy and various types of CHD, carvedilol treatment increased left 
ventricular ejection fraction (LVEF) and led to a decrease in human atrial natriuretic peptide (hANP)/ b-
type natriuretic peptide (BNP) blood levels [59].  
The only prospective randomized, double-blind, placebo-controlled trial evaluating beta-blockers in 
ACHD patients with heart failure was performed in patients after surgical correction of ToF with right 
ventricular failure who were in NYHA class I or II. No difference in blood levels of BNP, peak uptake of 
oxygen, NYHA class or effect on right and left ventricular volumes and ejection fractions as determined 
by magnetic resonance imaging was observed [60]. In contrast, a meta-analysis evaluating beta-blockers 
in pediatric and CHD patients with heart failure demonstrated a positive effect on echocardiographic 
parameters in patients with systemic left ventricular failure [61].  
In conclusion, there is currently insufficient data to give firm recommendations regarding the use of 
beta-blockers in ACHD patients with heart failure, although it might be considered in ACHD patients with 
aortic or mitral valve stenosis, especially when arrhythmias are also present [43].   
Renin-angiotensin-aldosterone system blockers and mineralocorticoid receptor antagonists  
Since angiotensin receptor enzyme (ACE) inhibitors reduce mortality and morbidity in patients with 
HFREF, they are recommended unless contraindicated in all symptomatic patients with heart failure [9]. 
Nonetheless, robust evidence for the implementation of ACE inhibitors in ACHD patients is lacking. Two 
studies described the use of ACE inhibitors in patients with repaired ToF. In the APPROPRIATE trial, 
ramipril had no effect on ventricular volume, functional class, severity of pulmonary regurgitation or 
peak oxygen uptake [62] in ToF patients with moderate to severe pulmonary regurgitation. 
Nevertheless, an improvement in LVEF and decrease in progression of diastolic function was 
demonstrated [63]. In another study of 95 ToF patients with a right ventricular ejection fraction <50% 
but without important pulmonary valvar disease, the angiotensin receptor blocker (ARB) losartan had no 
effect on right ventricular ejection fraction[64].  In patients with a systemic right ventricle no clear 
evidence supporting the use of ACE/ARB/MRAs is available yet. This is discussed in more detail below. 
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Mineralocorticoid/aldosterone receptor antagonists (MRA) are recommended in all HFREF patients 
already treated with ACE inhibitor and betablockers with a LVEF <35% who remain symptomatic [9]. 
Although studies in ACHD patients are lacking, in our opinion its use should be considered in heart 
failure patients with bi-ventricular physiology and a failing systemic left ventricle.   
 Diuretics   
Currently, there are no randomized clinical trials available demonstrating an effect of diuretics on 
morbidity or mortality in ACHD patients [42]. Still, these drugs are routinely used to treat the signs and 
symptoms of congestive heart failure in ACHD patients. A meta-analysis amongst non-ACHD heart 
failure patients, showed a significant increase in exercise capacity and reduction of the risk of death and 
worsening heart failure, supporting its use also in ACHD patients showing signs of congestion [65].   
 Digoxin  
Digoxin has a limited role in the treatment of heart failure in ACHD and non-ACHD patients, since no 
effect on mortality has been demonstrated [9, 42]. In a pediatric study among patients with left to right 
shunting and a preserved LVEF, digoxin showed no incremental decrease in proBNP on top of treatment 
with diuretics and ACE inhibitors [66]. Nonetheless, in our opinion it can still be considered in selected 
patients remaining symptomatic despite regular heart failure treatment, especially in those with atrial 
fibrillation, although there are studies describing an increased mortality in patients using digoxin [67]. 
However, this was not confirmed in other studies and more research is clearly needed  [68].    
 Novel therapies: Angiotensin receptor neprilysin inhibitors   
Angiotensin receptor neprilysin inhibitors (ARNIs) are a new class of therapeutic agents acting on the 
renin-angiotensin aldosterone system and the neutral endopeptidase system. In the most recent ESC 
guideline on heart failure, ARNIs have a class I recommendation in ambulatory patients with HFREF who 
remain symptomatic despite optimal treatment with an ACE-inhibitor, a beta-blocker and an MRA [9]. In 
the PARADIGM-HF trial, sacubitril/valsartan was superior to enalapril in reducing the risk of death and 
hospitalization for heart failure in patients with a reduced ejection fraction and NYHA class ≥ 2 [69].   
Although large prospective studies in ACHD patients are lacking, first study results were recently 
reported. In 15 patients with refractory heart failure despite guideline guided therapy, 
sacubitril/valsartan was initiated. No clinical deterioration was reported. In four patients in NYHA class 
III with complex ACHD, pulmonary hypertension and cyanosis, a significant improvement to NYHA class II 
was reported [70]. In a study of 23 patients with moderate/severe complexity ACHD, no improvement in 
functional class or systemic ventricular function, nor decrease in proBNP was described. In four patients, 
treatment was discontinued due to side effects [71].   
Ac
ce
pte
d M
an
us
cri
pt
Finally, in a small prospective study in patients with complex ACHD, 5 patients with severe systemic 
ventricular dysfunction in NYHA class II and III showed an improvement of one functional class after six 
months. Sacubitril/valsartan therapy was well tolerated [72].  
Since data from the first studies evaluating the use of sacubitril/valsartan in heart failure patients with 
ACHD are conflicting, further studies in larger cohorts are necessary to further evaluate the potential 
role of this novel therapy.  
  
Novel therapies: Sodium-glucose cotransporter 2 (SGLT2) inhibitors   
SGLT2 inhibitors including dapaglifozin have shown to reduce death and hospitalization and improve 
quality of life in patients with HFREF in patients with and without diabetes [73]. However, to our 
knowledge, no clinical trials evaluating its use in patients with ACHD have been conducted or are being 
conducted at present [74].   
 
4.3 Specific conditions 
 Heart failure in systemic right ventricle 
Patients with a systemic right ventricle are especially at risk for developing heart failure. Cuypers et al 
described an incidence of 23% in patients with Mustard correction of TGA during a median follow-up 
period of 35 years [13]. In patients with ccTGA, the prognosis might be slightly better. Nevertheless, by 
age 45, 76% of patients with ccTGA with associated lesions had congestive heart failure, while this was 
the case in 25% of ccTGA patients without associated lesions [15].   
In symptomatic patients with neurohumoral and cardiac autonomous nervous system activation, 
initiation of standard heart failure treatment is currently recommended. The efficacy of this treatment 
was recently described in a systematic review and meta-analysis [75]. Six studies with a total of 187 
patients were included. Because of the small numbers, betablockers could not be analyzed. After at 
least 3 months of treatment with ACE inhibitors, ARBs and MRAs, no significant change in mean ejection 
fraction, ventricular dimensions or peak ventilatory equivalent of oxygen was described. Recently, the 
long-term clinical outcome of a cohort of patients with a systemic right ventricle who were treated with 
valsartan was reported [76]. During a median follow-up period of 8.3 years, no improvement in survival 
was observed. However, there was a significant reduction in the risk for events, including heart failure 
(HR 0.37). Although the latter might underline the importance of the initiation of larger RCTs with longer 
follow-up, there is currently no robust evidence supporting the initiation of classic heart failure 
medication in patients with a systemic right ventricle. Therefore, in our opinion this should be reserved 
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for selected patients with signs and symptoms of heart failure and should not be routinely initiated in 
asymptomatic patients with an impaired systemic right ventricular function, although it might be 
difficult to accurately define “asymptomatic”.   
Trials evaluating the use of novel drugs in systemic right ventricles are currently ongoing. In 2017, the 
SERVE trial evaluating the effect of phosphodiesterase-5 inhibition was initiated, but no results were 
reported so far [77]. Although large trials evaluating the effect of sacubitril/valsartan in the systemic 
right ventricle are lacking, recently a small study in 23 patients with ACHD of moderate and severe 
complexity, including 12 patients with a systemic right ventricle, was reported. During a median follow-
up of 221 days, there was no improvement in systemic ventricular function or functional status [71].    
Fontan patients  
Similar to heart failure, in the failing Fontan circulation, the circulation can no longer meet the metabolic 
demands of the body. Clinically, mostly symptoms of right sided heart failure, including hepatic 
congestion, edema and ascites are present[78]. Although usually poorly tolerated, systolic or diastolic 
dysfunction might also be present.   
So far, no trials showed a beneficial effect on survival or exercise capacity using ACE inhibitors or 
MRAs[79, 80, 81]. Given the pre-load dependency of the Fontan patients, diuretics should be used with 
caution. In a cohort of 51 patients with an univentricular circulation, a potential beneficial effect of 
carvedilol on furosemide dosage and ejection fraction was described, although there are no other 
studies confirming these results yet [82].   
Since the Fontan circulation is greatly influenced by preload, the reduction of pulmonary vascular 
resistance might be beneficial in improving cardiac capacity and exercise capacity in Fontan patients. In 
a recently published meta-analysis, no beneficial effect of pulmonary vasodilators on mortality or NT-
proBNP levels was observed. However, a significant improvement in NYHA class, 6-minute walking 
distance and peak VO2 was described, as well as a small but significant reduction in mean pulmonary 
artery pressure [83]. The recently published FUEL trial exploring the use of udenafil versus placebo in 
400 Fontan patients (mean age 15,5 ±2 years) showed no significant effect on improvement in oxygen 
consumption at peak exercise [84]. However, in the udenafil group a significant improvement in the 
oxygen consumption, work rate, and ventilatory efficiency at the anaerobic threshold was observed. In 
conclusion, although no effect on mortality has been described yet, the use of pulmonary vasodilators in 
patients with a failing Fontan might be considered. 
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5. Non-medical treatment options  
 
5.1 Rehabilitation and lifestyle 
 
In acquired heart disease there is extensive evidence to encourage patients to pursue a healthy lifestyle 
[85, 86]. The role of cardiac rehabilitation programs in heart failure is instrumental in optimizing habits 
in nutrition, activity and smoking cessation, increasing physical fitness and improving quality of life and 
symptoms [87, 88]. In CHD evidence is less extensive, but several centers have shown the beneficial 
effects of exercise programs in different congenital conditions [89, 90]. Cardiopulmonary exercise 
testing can be a useful tool in assessing both baseline functional capacity and improvement after a 
rehabilitation program. Comparing an individual’s exercise capacity to peers with a similar congenital 
heart condition, gender and age is helpful in discussing a patient’s progress and daily life activities [91]. 
Different types of exercise training, such as endurance training or higher intensity interval training, can 
be used, tailored to the patient’s underlying pathology, capabilities and preference [92, 93]. Special 
consideration should be given to frequent arrhythmic events, systemic outflow tract obstruction and 
aortic dilatation [94]. A thorough and complete referral from the clinician to the rehabilitation team is 
essential in providing a safe and effective rehabilitation program, not only focusing on exercise 
capabilities, but also on nutrition, substance misuse and psychological factors. Currently, it is unclear 
what type of exercise-based cardiac rehabilitation is most suitable for heart failure patients with CHD 
[95]. However, in most cases the benefits of regular moderate exercise outweigh possible disadvantages 
and it is therefore important to discuss exercise options and offer high-quality rehabilitation programs. 
The risks of exercise seems low. A recently published position paper advocates an individualized exercise 
prescription for all adults with CHD [96]. 
 
5.2 Cardiac resynchronization and implantable defibrillator therapy  
 
The benefits of cardiac resynchronization therapy (CRT) in patients with heart failure with reduced 
ejection fraction and left bundle branch block (LBBB) are well established, aiming to reduce 
dyssynchrony of myocardial contraction and as such improving morbidity. It is a class IA 
recommendation for symptomatic patients in current heart failure guidelines of the European Society of 
Cardiology [9]. However, there are no specific recommendations related to CHD patients, and in clinical 
practice recommendations are often extrapolated to this specific patient group. The wide spectrum of 
Ac
ce
pte
d M
an
us
cri
pt
causes of dyssynchrony in the various underlying congenital conditions are one of the reasons that 
robust recommendations are lacking [97]. 
 
The role of CRT in patients with right bundle branch block (RBBB) or indeterminate interventricular 
conduction delay, so called non-LBBB, is less clearly defined compared to LBBB. A recent review [98] 
stated the high rate of non-responders for CRT in RBBB, although some subpopulations might benefit 
from CRT, specifically by using mapping techniques. In ACHD patients heart failure is often related to 
right ventricular dysfunction whether it serves as the subpulmonic or the systemic ventricle (e.g. in 
ccTGA, or after atrial switch of TGA), and may also include RBBB or other interventricular conduction 
abnormalities. At present, specific benefits for these situations are being elucidated in smaller studies 
[99]. 
 
A further indication for CRT in non-LBBB setting is the chance of developing heart failure due to 
permanent right ventricular pacing. Flugge et al showed that this is the most common indication for CRT 
in CHD patients in the German National Register for Congenital Heart defects [100]. 
 
When considering device implantation, it is important to pay diligent attention to the patient’s medical 
and surgical history before implantation. In patients with complex congenital conditions anatomical 
obstacles may hamper implantation. This may be related to previous surgeries such as atrial switch 
operations or Fontan procedures, to vascular access either congenital or due to previous endovascular 
procedures and to options for endo- or epicardial lead placement [101]. In patients with single ventricle 
physiology after the modified Fontan procedure, the role of CRT in significant ventricular dysfunction is 
not well studied. Demetriades et al highlight the anatomical difficulties in implantation of CRT in this 
patient group [102].  
 
In recent years, His bundle pacing is being explored as a more physiological mode of ventricular pacing 
in heart failure [103]. Its role in congenital heart disease is presently unclear and may be technically 
difficult due to anatomical variation and post-surgical changes of the His bundle and surrounding tissues 
in different congenital conditions [104].  
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The current lack of knowledge on the role of CRT in ACHD patients with heart failure highlights the need 
for more research in this particular area, as addressed in the 2018 AHA/ACC Guidelines on ACHD, in the 
section on “Evidence Gaps and Future Directions” [3]. 
 
Implantable cardiac defibrillators (ICD) are used to reduce the detrimental effects of ventricular 
arrhythmias and can be implanted for primary or secondary prevention.  In the case of secondary 
prevention, there is a well-established indication to prevent recurrence of life-threatening ventricular 
tachycardia and/or fibrillation which also applies to ACHD patients. Primary prevention of ventricular 
arrhythmias in ACHD is more complex with higher risk conditions which often do not coincide with 
clinical heart failure, contrary to non-congenital causes of heart failure [105, 106]. There is consistent 
evidence about the risk of sudden cardiac death in a subset of ToF patients. Khairy et al proposed a risk 
score based on 6 variables: prior palliative shunt, inducible sustained VT, QRS duration > 180ms, 
ventriculotomy incision, non-sustained VT and left ventricular end diastolic pressure > 12mmHg [107]. In 
patients with significant impairment of the systemic right ventricle it is as yet uncertain whether they 
benefit from primary ICD placement. At the moment, it is not routinely recommended. Further clinical 
research is required to refine risk stratification for ventricular arrhythmias [108, 109] and to minimize 
the occurrence of inappropriate ICD shocks [110, 111]. In a considerable proportion of ACHD patients 
subcutaneous ICD implantation seems suitable [112]. In addition to risk assessment and technical 
considerations, special care should be given to the psychological impact of ICDs and the effect it may 
have on quality of life and mental health, with higher anxiety levels and diminished general health 
perception and physical functioning reported [113, 114].  
 
 
6. Advanced therapy  
Heart transplantation (HT) is possible in ACHD patients. However, meticulous planning before 
transplantation, including evaluation using multiple imaging modalities, decisions regarding cannulation 
strategy and correction of residual anatomic lesions, is crucial. The 30-day mortality has improved from 
14,3% before 2010 to 6.8% between 2010 and 2014 [115]. However, early mortality after heart 
transplant is higher in ACHD than in non-CHD patients (18.9% vs. 9.6%)[116]. After the initial 30 days 
patients with ACHD have a superior long-term survival compared with non-CHD adults [117]. In the 
Fontan population mortality remains high [118]. Identifying the appropriate time for successful heart 
transplant is one of the most difficult aspects of caring for adults with CHD. Adults with CHD who have 
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end-organ dysfunction or elevated PVR that precludes HT may improve with mechanical unloading and 
later become eligible for HT. Increased attention has thus turned to using mechanical circulatory 
support (MCS), such as ventricular assist devices (VADs) as a bridge-to-transplant, bridge-to-decision, or 
destination therapy. Adults with CHD had similar improvement in functional status and quality of life 
compared with non-CHD patients [119]. Furthermore, adults with CHD bridged to HT with a ventricular 
assist device (VAD) had survival comparable to those transplanted directly, despite worse baseline 
functional status and more co-morbidities. Taken together, these studies indicate that MCS is 
appropriate in selected patients. Patients with d-TGA corrected by atrial switch and l-TGA frequently 
develop systemic right ventricular failure as adults and may require VADs, which is more difficult but 
possible [120]. Surgically, the pyramidal geometry of a morphological right ventricle frequently 
necessitates resection of trabeculae and/or alternate positioning of the inflow cannula, often on the 
diaphragmatic surface or free wall [121]. Patients with baffles may require higher central venous 
pressures due to their inherent diastolic dysfunction from baffle stiffness, and they are at risk of 
obstruction from pulmonary artery catheters. 
 
 
7. Advanced care planning 
Advanced care planning (ACP) is a process that supports and empowers individuals, at any stage of their 
lives or the disease process, to consider and communicate preferences for future health care to their 
loved ones and health care providers . During this process, individuals have the opportunity to make 
decisions in advance about treatment they would and would not want, should they be unable to express 
their wishes at that time. This process benefits patients by increasing the likelihood that their wishes be 
followed but also health care providers by providing information sufficient to align treatment plans with 
patient goals and preferences. The majority of ACHD patients report interest in ACP independent of the 
underlying defect severity and prefer that such discussions be initiated early in the disease course, 
before life-threatening complications occur. In one study, 18 years of age was identified as the most 
appropriate age to initiate an ACP dialogue [122]. Although most adults with CHD report interest in ACP 
and in receiving information about the life expectancy of individuals with their type of CHD, some may 
not. Ideally, ACP is a gradual process that is initiated by exploring a person’s understanding of the aims 
and potential benefits of ACP and discussion of their personal readiness [123]. Information about health-
related experiences, values, psycho-social resources, concerns and expectations should be sought. Open 
and sensitive communication concordant with personal needs and values should include an explanation 
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of how the CHD diagnosis impacts longer term health expectations as well as anticipated disease 
progression, prognosis, and the advantages and disadvantages of potential treatment options. Should 
their condition deteriorate further, and the estimated life-expectancy decline to 1-2 years, discussions 
can be extended with specific questions related to wishes at the end-of-life, including issues related to 
the modification of cardiac devices (e.g. deactivation of ICD shock function) and other management 
choices at end of life, including palliative care measures. Some patients have a reduced life expectancy, 
such as adults with Fontan procedure, adults with cyanotic heart disease and adults with a systemic 
right ventricle approaching 40 years of age.  It is very important to provide written documentation in 
medical records of elements discussed and share this information with the general practitioner and 
other healthcare professionals. If necessary social care, palliative care teams and/or psychological and 
religious support services should be involved [124]. A position paper discussing this topic from the ESC 
Working Group of Adult Congenital Heart will soon be published [125].  
 
 
8. Conclusion 
The growing number of patients with congenital heart disease who develop heart failure poses an 
important challenge in terms of diagnosis and treatment, both medical and non-medical. It requires a 
comprehensive evaluation of the clinical status by different diagnostic techniques. Knowledge and 
interpretation of evolving diagnostic and therapeutic options is paramount in delivering the best 
available care. More attention for implementing biomarkers is necessary. Evidence for a positive effect 
of medical treatment is absent and more research is clearly needed. 
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9. Expert opinion 
The astonishing advances in the care and treatment of congenital heart disease (CHD) in the recent 
decades have undoubtedly had a positive impact on both life expectancy and morbidity. Nowadays most 
patients survive into adulthood and present adult cardiologists with distinct and challenging issues. 
Among these, heart failure occurs often and has a significant impact on mortality, morbidity and quality 
of life. There is a need for medical research to guide physicians and to deliver the best possible care in 
these patients. This need was highlighted in the 2018 American guidelines on adult congenital heart 
disease and is recognized by adult cardiologists in CHD worldwide. 
 
It is important to establish a well-rounded diagnostic process for the individual patient with any signs of 
heart failure or reduced exercise capacity, comprising of several tests including imaging, laboratory tests 
and invasive techniques. The diagnosis might be difficult because all patients have an underlying 
structural heart abnormality and many have had subnormal exercise capacity for years. There is 
emerging evidence that the use of biomarkers is helpful for the clinician. Markers that are well-
established in general cardiology practice, such as high-sensitive troponin and NT-proBNP, have shown 
to also improve the accuracy of heart failure diagnosis in CHD. In our opinion, biomarkers ought to be 
one of the cornerstones of evaluating heart failure and possibly guiding treatment. Therefore, the 
implementation of biomarkers needs more attention and more research demonstrating the value of this 
diagnosticon is warranted.  
 
Research in the field of treatment of ACHD is challenging and has several obstacles, related to the 
heterogenic nature of the population due to multiple factors including the underlying pathology, 
interventions in childhood, relevant co-morbidities, psychosocial factors and geographical and historical 
differences in treatment. Currently, no clear evidence supporting medical treatment is available. This 
can be explained by the fact that most available research and clinical guidelines are based on single 
center, non-randomized studies in small patient groups. This has been recognized by the ACHD 
community and more centers are now working together internationally in setting up collaborations to 
study the important questions in diagnosis and treatment at this moment. These multicenter 
collaborations will also facilitate future research on emerging issues, such as new drug treatments and 
non-medical treatment options. This is also relevant when more effective options become available, 
especially the promising recently developed medications, such as the angiotensin-receptor-neprilysin-
inhibitors or the sodium-glucose transport protein 2- inhibitors. We therefore urge our colleagues in the 
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field of ACHD worldwide to expand current collaborations in order to perform large prospective studies 
or registries in specific patient groups to better understand what treatments are effective. 
 
In this relatively young patient group, it is essential to consider and discuss, despite their age, advanced 
treatment options and advanced care planning when a heart failure diagnosis is made. Patients deserve 
to be fully informed about prognosis and treatment options, such as implantable devices, mechanical 
support and heart transplantation, and whether these options apply to their specific situation. 
Compassionate and repeated conversations about advanced care planning will help our patients, and 
their families, in dealing with grief, loss and end-of-life issues. Furthermore, it will help physicians and 
nurses involved in the care of the patient. These important conversations should not be neglected or left 
to the last moment. Consultation with heart failure specialist and palliative care specialists is essential in 
these issues. 
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Heart failure is an increasing clinical entity in ACHD patients, urging the medical community to timely 
discuss advanced care planning in this rapidly expanding patient category. Some important insight 
regarding this topic will be discussed in this paper.  
 
 
 
 
 
 
 
